Navigation Links
NeoVista, Inc. Presents New Data on Its Novel Wet AMD Therapy at AAO
Date:11/12/2007

this study demonstrated its differences from previous attempts by the medical community to use radiation for the treatment of wet AMD. Additional on-going studies may well confirm the viability of this new therapeutic option for the elderly with wet AMD."

Unlike previous forms of radiation therapy for Wet AMD, NeoVista's approach delivers the peak dose of radiation directly to the lesion without damaging the underlying choroidal vasculature. Utilizing strontium-90, the focused radiation is delivered to a target area 3 mm in depth and up to 5.4 mm in diameter. Importantly for patients, the systemic exposure to radiation is minimal, as the effective dose to the entire body from NeoVista's epiretinal device is comparable to 15 minutes of exposure to the sun.

"The ultimate promise of this therapy revolves around that fact that NeoVista's targeted radiation delivery system allows patients to continue living their lives, with significantly less injections, while also having the potential to save both patients and the healthcare system billions of dollars," said John N. Hendrick, President and CEO of NeoVista. "We look forward to unveiling the true impact of our therapy on patients and physicians now that our larger CABERNET trial is underway."

The CABERNET (CNV Secondary to AMD Treated with BEta RadiatioN Epiretinal Therapy) trial is a multi-center, randomized, controlled study which will enroll 450 subjects at 30 sites worldwide (20 in the United States). The study will evaluate the safety and efficacy of NeoVista's beta radiation epiretinal therapy delivered concomitantly with the FDA approved antiangiogenic therapy, Lucentis(R), versus Lucentis(R) alone.

About NeoVista, Inc.

NeoVista, Inc. is a privately held development-stage medical device company based in Fremont, California. NeoVista's beta radiation epiretinal therapy is currently being studied in a definitive clinical study to support eventual filing for regulatory approval to market
'/>"/>

SOURCE NeoVista, Inc.
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. Genaera Corporation Presents Interim Phase 1 Data for Obesity Compound Trodusquemine (MSI-1436) at IBC Conference
2. EntreMed Presents Data for Phase 2 Study of MKC-1 in Metastatic Breast Cancer
3. Pharmasset Presents R7128 Phase 1 Single Ascending Dose Study in Healthy Volunteers
4. Anadys Pharmaceuticals Presents Preclinical Results on ANA598, a Non-Nucleoside Inhibitor of the NS5B Polymerase, at the 14th International Symposium on Hepatitis C Virus and Related Viruses
5. CEL-SCI Presents Data for CEL-1000 as a Vaccine Adjuvant with Recombinant Hepatitis B Virus Protein
6. Ardea Biosciences, Inc. Presents Results of Phase 1 Studies of RDEA806, a Novel NNRTI for HIV, at 47th ICAAC
7. Targanta Presents First Data Demonstrating In Vitro Activity and In Vivo Efficacy of Prodrugs in Osteomyelitis Models
8. Wyeth Presents Phase 3 Fracture Data for Bazedoxifene, an Investigational Therapy for Osteoporosis
9. Aegerion Pharmaceuticals, Inc. Presents Final Results of Phase II Clinical Trials for AEGR-733 at Drugs Affecting Lipid Metabolism (DALM) 2007 Conference
10. Surface Logix Presents Positive Phase 1 Repeat-Dose Trial Data on SLx-4090 at The 16th International Symposium on Drugs Affecting Lipid Metabolism
11. Wyeth Presents New Phase 3 Data and Updates Regulatory Timing for NDA Filing of Bazedoxifene/Conjugated Estrogens
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/7/2015)... 2015 A power morcellator lawsuit ( http://www.morcellatorlawsuit2015.com ... for an undisclosed amount, Bernstein Liebhard LLP reports. According ... 2014 in the U.S. District Court, Eastern District of ... widower whose wife had died in February 2013, just ... involved the use of a power morcellator. Following the ...
(Date:7/7/2015)... Juli 2015 Sequent Medical, ein ... Entwicklung innovativer Geräte für die Behandlung neurovaskulärer ... von R. Michael Kleine in den ... verfügt über eine mehr als 25-jährige Erfahrung ... hat verschiedene globale biomedizinische Unternehmen erfolgreich geleitet ...
(Date:7/7/2015)... -- According to a new market research report ... Instrument), Application (Aerobic, Anaerobic, Yeast/ Fungi) & End User (Hospital, ... 2019", published by MarketsandMarkets, The global Blood Culture Tests Market ... Million in 2014 at a CAGR of 7.2% from 2014-2019. ... ma rket data T ables and ...
Breaking Medicine Technology:Lina Medical, Power Morcellator Lawsuit Plaintiff Reach Settlement in Case Scheduled for November Trial, Bernstein Liebhard LLP Reports 2Lina Medical, Power Morcellator Lawsuit Plaintiff Reach Settlement in Case Scheduled for November Trial, Bernstein Liebhard LLP Reports 3Sequent Medical beruft Mike Kleine in den Aufsichtsrat 2Sequent Medical beruft Mike Kleine in den Aufsichtsrat 3Blood Culture Tests Market Worth $3,893.5 Million by 2019 2Blood Culture Tests Market Worth $3,893.5 Million by 2019 3Blood Culture Tests Market Worth $3,893.5 Million by 2019 4
... Boston Scientific Corporation (NYSE: BSX ) ... MADIT-CRT trial data in the current issue of the ... showed women received a greater clinical benefit from cardiac ... sub-analysis demonstrated that both men and women experienced significant ...
... CUPERTINO, Calif., Feb. 8, 2011 DURECT Corporation (Nasdaq: ... CreoSalus, Inc., has launched commercial sales of its Food ... Equine, an injectable animal health drug utilizing DURECT,s SABER™ ... a royalty on net sales of SucroMate and will ...
Cached Medicine Technology:Boston Scientific Welcomes Publication of Gender Data Highlighting Benefits Women Receive From CRT-Ds 2Boston Scientific Welcomes Publication of Gender Data Highlighting Benefits Women Receive From CRT-Ds 3Boston Scientific Welcomes Publication of Gender Data Highlighting Benefits Women Receive From CRT-Ds 4DURECT Announces Launch of First FDA Approved SABER™-Injectable Peptide Product 2DURECT Announces Launch of First FDA Approved SABER™-Injectable Peptide Product 3
(Date:7/7/2015)... and CHICAGO (PRWEB) , ... July 07, 2015 ... ... healthcare business development and growth strategy expert Jay Warden as Senior Vice President, ... for the company’s efforts to provide the best solutions to healthcare providers’ needs ...
(Date:7/7/2015)... ... July 07, 2015 , ... More than ... Dial and Howdy’s, raised more than $524,286 during the Muscular Dystrophy Association's ... $100,000, to help support children fighting muscular dystrophy and related life-threatening diseases ...
(Date:7/7/2015)... York, NY (PRWEB) , ... July 07, 2015 , ... ... thing that can help pass those long, stressful days at work is knowing that ... aren’t always as laid back and stress free as imagined. Planning for a vacation ...
(Date:7/7/2015)... ... July 07, 2015 , ... This week Northeast Nebraska Imaging, ... website. The website’s goal is to provide patients with detailed information about the ... requesting appointments online. , Part of the center’s rebranding efforts, the website was ...
(Date:7/7/2015)... ... July 07, 2015 , ... Seattle-based ... have merged to form Camber Collective. Camber Collective provides strategic advisory services ... SwitchPoint’s strategy consulting expertise with Hope Consulting’s deep experience in customer insights, ...
Breaking Medicine News(10 mins):Health News:Hammes Company Hires Jay Warden to Lead Healthcare Advisory Services 2Health News:Hammes Company Hires Jay Warden to Lead Healthcare Advisory Services 3Health News:Western Refining Raises $524,286 to Help Send Kids with Neuromuscular Disease to MDA Summer Camp 2Health News:Western Refining Raises $524,286 to Help Send Kids with Neuromuscular Disease to MDA Summer Camp 3Health News:Difass USA Offers Eight Tips to Help Relax and Enjoy Summer Vacation 2Health News:Difass USA Offers Eight Tips to Help Relax and Enjoy Summer Vacation 3Health News:Northeast Nebraska Imaging Launches New Patient Friendly Website 2Health News:SwitchPoint and Hope Consulting Have Merged to Form Camber Collective 2
... N.C., Jan. 29 In today,s volatile ... unwary,pharmaceutical company and nullify product forecasts, sales ... on competitors,products and operations, a high-functioning Competitive ... opportunities as well as warn,them about potential ...
... Collaboration with Harvard Medical International Provides ... Vital Global Health Information, BALTIMORE, Jan. 29 ... reach of their groundbreaking MEDEX,360m partnership with the launch ... and leisure travelers., Like the original MEDEX 360m ...
... that it takes 50,000 lying side by side to equal ... to be highly accurate vehicles for administering medicines and other ... what happens to the tubes after they discharge their medical ... Now, Stanford researchers, who spent months tracking the tiny tubes ...
... an in utero stem cell treatment could lead to ... as a range of other disabling,conditions, according to a ... (UQ). , Action Medical Research has announced the outcomes ... led by Professor Nicholas Fisk, that could lead to ...
... of DNA in the human genome that originated from ... bodies and are even essential for a healthy pregnancy, ... Microbiology Today. , Retrovirus infections represent the most intimate ... genome into the DNA of the host cell, resulting ...
... security, reduces risk and ... supports ... global,provider of integrated security, risk and audit management solutions, today,announced ... Service (NHS) has selected its flagship SecureVue(R) platform to,proactively manage ...
Cached Medicine News:Health News:Building and Sustaining Impactful Competitive Intelligence Organizations for Pharma 2Health News:MEDEX / Harvard Partnership Now Offers Affordable, New Intelligence to Individual Business & Leisure Travelers 2Health News:New nanotube findings by Stanford researchers give boost to potential biomedical applications 2Health News:New nanotube findings by Stanford researchers give boost to potential biomedical applications 3Health News:Stem cell treatment for brittle bones in the womb 2Health News:The North Western Deanery of UK's National Health Service Selects eIQnetworks' SecureVue for Comprehensive IT Assurance 2Health News:The North Western Deanery of UK's National Health Service Selects eIQnetworks' SecureVue for Comprehensive IT Assurance 3
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
... a national reference laboratory and a worldwide ... ARUP offers an extensive test menu of ... clinical and anatomic pathology. Owned by the ... more than half of the nation's university ...
... national reference laboratory and a worldwide leader ... offers an extensive test menu of highly ... and anatomic pathology. Owned by the University ... than half of the nation's university teaching ...
... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...
Medicine Products: